A new experimental obesity drug is outperforming traditional weight-loss treatments in early research. Developed by the Institute for Diabetes and Obesity at Helmholtz Munich, the drug, GLP-1-GIP-Lani, is a quintuple agonist that targets five receptor systems. It combines GLP-1 and GIP hormones with PPAR activity to improve insulin sensitivity, fat metabolism, and liver health.
Researchers describe it as a "Trojan horse," where the incretin component allows entry into cells, and the PPAR "cargo" activates to enhance insulin use and reduce inflammation. This mechanism may enable lower dosing and fewer side effects.
In preclinical mouse models, the compound lowered body weight, food intake, fat mass, and blood sugar more effectively than GLP-1 and GIP alone. It also outperformed semaglutide. Gastrointestinal side effects were similar to existing therapies.
Dr. Peter Balazs, a hormone and weight-loss specialist in New York and New Jersey, noted that the drug targets obesity and insulin resistance at multiple key sites simultaneously. He explained it functions as both an "appetite brake" and a "metabolic engine." However, he cautioned that the study was only on mice, with no human safety or efficacy data yet.
The next step is to optimize the approach for humans and move toward clinical trials.